Edwin Reisz Sells 60,769 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Edwin Reisz sold 60,769 shares of Aveanna Healthcare stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total transaction of $438,144.49. Following the sale, the insider owned 1,447,057 shares in the company, valued at approximately $10,433,280.97. This represents a 4.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Aveanna Healthcare Trading Down 1.1%

Shares of NASDAQ AVAH opened at $7.34 on Friday. The firm has a 50 day moving average price of $8.45 and a two-hundred day moving average price of $8.46. The stock has a market cap of $1.53 billion, a P/E ratio of 20.39 and a beta of 2.06. Aveanna Healthcare Holdings Inc. has a 52-week low of $3.67 and a 52-week high of $10.32. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. BMO Capital Markets began coverage on Aveanna Healthcare in a research note on Thursday, November 13th. They issued an “outperform” rating and a $11.00 price target for the company. Raymond James Financial reiterated an “outperform” rating and issued a $13.00 target price on shares of Aveanna Healthcare in a report on Friday, December 5th. Zacks Research downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Monday, December 29th. Finally, Royal Bank Of Canada boosted their price target on shares of Aveanna Healthcare from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Thursday, January 15th. Five analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Aveanna Healthcare currently has a consensus rating of “Hold” and a consensus target price of $11.06.

Key Stories Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Institutional buying in recent quarters — firms including Invesco, Millennium, Zimmer Partners and others increased or established positions in Q4, a vote of confidence that can support the stock over the medium term. MarketBeat Institutional Activity
• Positive Sentiment: Despite recent sales, insiders still retain large, multi‑million‑dollar stakes (CEO, CFO and others remain major shareholders), which can temper panic selling and signal some continued alignment with shareholders. SEC Filing
• Neutral Sentiment: Reported short interest shows zero shares for mid‑February — this is almost certainly a reporting/data anomaly and does not indicate genuine lack of short interest. Treat the short‑interest figure cautiously. Short Interest Data
• Neutral Sentiment: Trading volume today was below recent averages; low volume can amplify price moves when large blocks or news hit the tape (higher intraday volatility risk).
• Neutral Sentiment: Analyst coverage remains mixed: consensus is around a “Hold” with an average target near $11 — helpful context for longer‑term positioning but not an immediate catalyst. Analyst Summary
• Negative Sentiment: Large, concentrated insider selling Feb. 17–19 by CEO Jeff Shaner — roughly 461,900 shares sold across three days (~$3.4M reported proceeds) — is the primary negative catalyst driving downward pressure as the market interprets sizeable CEO disposals as risk reduction. CEO Sales SEC Filing
• Negative Sentiment: Additional senior/executive selling (CFO Matthew Buckhalter, CAO Deborah Stewart, and other insiders including Edwin C. Reisz and Patrick A. Cunningham) involved hundreds of thousands of shares total across the same dates — a reinforcing negative signal that likely amplified the pullback. Other Insider Filings
• Negative Sentiment: Independent coverage singled out the insider selling as the main reason for a recent ~5–6% pullback, increasing market attention on the disposals and reinforcing short‑term selling pressure. AAII Article

Institutional Trading of Aveanna Healthcare

Several large investors have recently modified their holdings of AVAH. Quantbot Technologies LP bought a new stake in shares of Aveanna Healthcare in the 2nd quarter valued at $43,000. Lion Street Advisors LLC acquired a new stake in Aveanna Healthcare in the third quarter worth $89,000. MQS Management LLC bought a new stake in Aveanna Healthcare in the second quarter valued at $59,000. EverSource Wealth Advisors LLC increased its stake in Aveanna Healthcare by 88,100.0% in the third quarter. EverSource Wealth Advisors LLC now owns 11,466 shares of the company’s stock valued at $102,000 after purchasing an additional 11,453 shares in the last quarter. Finally, Belvedere Trading LLC acquired a new position in shares of Aveanna Healthcare during the second quarter valued at about $62,000. Institutional investors and hedge funds own 87.96% of the company’s stock.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.